Eight-year outcomes from the WHiTE3 HEMI trial
At one year, a significantly higher mortality rate was noted in the Thompson group. At long-term follow-up, Thompson and Exeter Unitrax demonstrated equivalent and low reoperation rates and excellent implant survivorship. Further studies may look to validate these findings.
Authors
- Sameer Khan (ORCID: https://orcid.org/0000-0003-4086-6047)
- Ben Tyas (ORCID: https://orcid.org/0000-0002-7858-4988)
- Nick Parsons (ORCID: https://orcid.org/0000-0001-9975-888X)
- Mike Reed (ORCID: https://orcid.org/0000-0002-6309-2710)
- Timothy Petheram (ORCID: https://orcid.org/0000-0002-2649-0402)
- Dominic Inman (ORCID: https://orcid.org/0000-0002-6713-7058)
- Andrew Chaplin
- Alex L. Sims
Institutions
- Northumbria Healthcare NHS Foundation Trust (GB)
- University of Warwick (GB)
- Northern Devon Healthcare NHS Trust (GB)
- Health Education North West (GB)
Publication Details
- Journal
- Bone & Joint Open
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1302/2633-1462.610.bjo-2025-0106.r1
- Primary Topic
- Hip and Femur Fractures
- Type
- article
- Field-Weighted Citation Impact
- 0.00